Novo Nordisk and Eli Lilly Face Lawsuits Over Alleged GLP-1 Vision Loss Risks

Key facts

The litigation against Novo Nordisk and Eli Lilly marks an expanding legal battle over the safety profile of the world's most widely prescribed weight-loss and diabetes medications. Across federal and state jurisdiction courts in the United States, patients have filed personal injury claims asserting that taking semaglutide or tirzepatide resulted in permanent optic nerve damage and partial or total blindness.

The claims specifically focus on non-arteritic anterior ischemic optic neuropathy (NAION), a medical condition characterized by sudden, painless loss of vision caused by reduced blood flow to the head of the optic nerve. Plaintiffs contend that the pharmaceutical companies knew or should have known about potential microvascular risks associated with GLP-1 receptor stimulation, yet failed to disclose these risks on product packaging, prescribing guidelines, or marketing materials provided to healthcare practitioners.

This new wave of ocular lawsuits broadens the legal challenges facing both manufacturers. Prior product liability claims against Novo Nordisk and Eli Lilly primarily centered on gastrointestinal complications, including severe gastroparesis—commonly described as stomach paralysis—as well as intestinal blockages, persistent vomiting, and severe dehydration. The addition of vision loss allegations introduces a distinct category of permanent harm that requires specialized medical discovery and expert epidemiological evidence.

The rapid growth in prescriptions for Ozempic, Wegovy, Mounjaro, and Zepbound has been fueled not only by clinical trial results but also by unprecedented viral popularity across mainstream culture. High-profile figures have frequently discussed their use of injectable weight-loss treatments in media appearances and online platforms. Tesla and SpaceX chief executive Elon Musk publicly credited GLP-1 injectables for his physical transformation, while television icon Oprah Winfrey hosted dedicated broadcast specials on obesity medicine and discussed her reliance on weight-management drugs. Internationally, popular digital personalities, including Indian comedian and content creator Tanmay Bhat, brought discussions of injectable weight-loss treatments to millions of online followers, normalizing their use across diverse global demographics.

Why it matters

The surge in lawsuits alleging permanent eye damage presents significant consequences for public health, regulatory standards, medical practice, and financial markets. Millions of patients worldwide rely on GLP-1 and dual GLP-1/GIP medications for chronic condition management, including Type 2 diabetes, clinical obesity, and related cardiovascular risk factors. The legal allegations raise immediate safety concerns for prescribing physicians and patients who must weigh the metabolic benefits of treatment against potential microvascular risks.

If court proceedings establish that manufacturers omitted essential safety warnings, federal regulators such as the U.S. Food and Drug Administration (FDA) and international bodies like the European Medicines Agency (EMA) may face calls to mandate updated product labeling, black-box warnings, or formal post-marketing clinical trials examining ocular vascular health.

For Novo Nordisk and Eli Lilly, the litigation introduces potential long-term financial liabilities and reputational risks. Both corporations have achieved historic market capitalizations largely driven by exponential sales growth in their GLP-1 product lines. Extensive tort litigation, potential multidistrict settlement negotiations, and legal defense costs could impact corporate earnings and future research investments. Furthermore, the outcome of these cases will test pharmaceutical failure-to-warn legal doctrines, establishing benchmarks for how drug manufacturers must evaluate, report, and communicate emerging safety signals associated with systemic therapies that alter metabolic and vascular pathways.

GLP-1 receptor agonists function by mimicking natural gut hormones that stimulate insulin secretion, inhibit glucagon release, delay gastric emptying, and signal fullness to the brain. Novo Nordisk developed semaglutide, receiving FDA approval for Type 2 diabetes under the brand name Ozempic in 2017 and for chronic weight management under the name Wegovy in 2021. Eli Lilly developed tirzepatide, a dual-action drug targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, winning FDA approval for diabetes under the brand name Mounjaro in 2022 and for weight management under the name Zepbound in 2023.

As sales surged worldwide, medical researchers began examining secondary physiological effects associated with GLP-1 therapies. Early clinical trials had noted instances of diabetic retinopathy complications among diabetes patients who experienced rapid reductions in blood glucose levels. However, concerns regarding optic nerve damage broadened significantly following observational medical studies.

In July 2024, researchers from Harvard Medical School and Massachusetts Eye and Ear published a study in JAMA Ophthalmology analyzing patient records over several years. The study observed that patients prescribed semaglutide for diabetes or weight loss exhibited higher diagnosed rates of NAION compared to patients taking non-GLP-1 medications for the same conditions. While observational research establishes association rather than direct biological causation, the published findings catalyzed product liability attorneys to begin reviewing potential claims from patients who experienced sudden vision impairment while using GLP-1 injectables.

In the U.S. legal system, complex product liability lawsuits involving widespread consumer products are frequently organized through Multidistrict Litigation (MDL). Under this federal procedure, individual lawsuits filed across different judicial districts are consolidated before a single federal judge for coordinated pre-trial proceedings, evidentiary motions, and bellwether trials. A federal judicial panel had previously established an MDL in the U.S. District Court for the Eastern District of Pennsylvania to coordinate litigation regarding GLP-1 gastrointestinal injuries, setting a procedural framework for managing mass tort claims involving these medications.

Reaction

Novo Nordisk and Eli Lilly have consistently defended the safety, efficacy, and clinical testing of their GLP-1 product portfolios. In formal statements regarding ongoing mass tort litigation, both manufacturers emphasize that their medications underwent rigorous multi-phase clinical trial programs evaluated by global regulatory agencies prior to approval.

Industry representatives contend that existing prescribing information already provides appropriate guidance to physicians regarding microvascular and ocular monitoring, particularly for patients with existing diabetic retinopathy or long-standing cardiovascular disease. The drugmakers argue that scientific literature does not prove a direct causal link between GLP-1 receptor agonist therapies and NAION or permanent blindness. They point out that conditions such as Type 2 diabetes, hypertension, high cholesterol, and obstructive sleep apnea represent well-established independent risk factors for optic nerve ischemia.

Legal representatives for plaintiffs maintain that manufacturers possessed sufficient adverse event data to warrant explicit warnings on packaging inserts. Meanwhile, medical professional organizations, including endocrinology and ophthalmology societies, have urged patients not to stop taking prescribed GLP-1 medications without consulting their medical providers, cautioning that abrupt cessation of diabetes and weight management therapies can cause sharp spikes in blood sugar and elevate overall health risks.

What we don't know yet

Significant scientific, regulatory, and legal questions remain open in the ongoing dispute over GLP-1 medications and vision loss:

What to watch

Several key developments will dictate the progression of GLP-1 vision loss litigation and regulatory oversight in the coming months:

This report is based on coverage by Mashable News Staff.